Marked gender differences in progression of mild cognitive impairment over 8 years
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.089 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
Abstract Introduction This study examined whether, among subjects with mild cognitive impairment (MCI), women progressed at faster rates than men. Methods We examine longitudinal rates of change from baseline in 398 MCI subjects (141 females and 257 males) in the Alzheimer's Disease Neuroimaging Initiative‐1, followed for up to 8 years (mean, 4.1 ± 2.5 years) using mixed‐effects models incorporating all follow‐ups (mean, 8 ± 4 visits). Results Women progressed at faster rates than men on the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐Cog; P = .001) and clinical dementia rating‐sum of boxes (CDR‐SB; P = .003). Quadratic fit for change over time was significant for both ADAS‐Cog ( P = .001) and CDR‐SB ( P = .004), and the additional acceleration in women was 100% for ADAS‐Cog and 143% for CDR‐SB. The variability of change was greater in women. The gender effect was greater in apolipoprotein E ( APOE ) ε4 carriers. Discussion Women with MCI have greater longitudinal rates of cognitive and functional progression than men. Studies to confirm and uncover potential mechanisms appear to be warranted. Trial Registration ADNI ClinicalTrials.gov identifier: NCT00106899 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Topic
- Dementia and Cognitive Impairment Research
- Field
- Medicine
- Canadian institutions
- —
- Funders
- National Institute of Biomedical Imaging and BioengineeringNational Institute on AgingCanadian Institutes of Health ResearchNational Institutes of HealthServierGenentechInnogeneticsEisaiTakeda Pharmaceutical CompanyBiogen IdecMedpaceNovartisGE HealthcareBioClinicaU.S. Department of DefenseMeso Scale DiagnosticsAlzheimer's Disease Neuroimaging InitiativePfizerEli Lilly and CompanySynarcMerck
- Keywords
- Cognitive impairmentMedicineCogAlzheimer's Disease Neuroimaging InitiativeNeuroimagingInternal medicineLongitudinal studyCognitionCognitive agingGerontologyCognitive declinePsychologyDemographyDiseaseDementiaPsychiatryPathology
- Has abstract in OpenAlex
- yes